BRVE 10-Q: SEC filing
Braveheart Bio, Inc.
Filed with the SEC on · accession 0001628280-26-072709
BRVE filed a 10-Q (quarterly report) with the SEC on Nov 10, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +0.8% by the first close after the filing.
Summary of the filing
Braveheart Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including an IPO completed in August 2026 and related-party transactions with Jiangsu Hengrui Pharmaceuticals.
Key details
How BRVE stock reacted
Close before
$19.46
Nov 9, 2026
First close after
+0.82%
$19.62
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for BRVE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BRVE?
Click hereFrequently asked questions
What did BRVE file with the SEC on Nov 10, 2026?
BRVE filed a 10-Q (SEC filing). Braveheart Bio, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including an IPO completed in August 2026 and related-party transactions with Jiangsu Hengrui Pharmaceuticals.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did BRVE stock react to this filing?
BRVE closed at $19.46 before the filing and $19.62 on Nov 10, 2026 (+0.82%).
Other BRVE SEC filings
Get alerts when BRVE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days